SG11201900200XA - Tgfb antibodies, methods, and uses - Google Patents

Tgfb antibodies, methods, and uses

Info

Publication number
SG11201900200XA
SG11201900200XA SG11201900200XA SG11201900200XA SG11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA SG 11201900200X A SG11201900200X A SG 11201900200XA
Authority
SG
Singapore
Prior art keywords
international
protgfb1
massachusetts
johnson
rule
Prior art date
Application number
SG11201900200XA
Other languages
English (en)
Inventor
Gregory J Carven
Thomas Schurpf
Katherine Turner
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of SG11201900200XA publication Critical patent/SG11201900200XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11201900200XA 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses SG11201900200XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05
PCT/US2017/042162 WO2018013939A1 (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Publications (1)

Publication Number Publication Date
SG11201900200XA true SG11201900200XA (en) 2019-02-27

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900200XA SG11201900200XA (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Country Status (13)

Country Link
US (2) US20190292254A1 (ko)
EP (1) EP3484499A4 (ko)
JP (2) JP7128801B2 (ko)
KR (1) KR102577551B1 (ko)
CN (1) CN110049773A (ko)
AU (1) AU2017294772B2 (ko)
BR (1) BR112019000621A2 (ko)
CA (1) CA3030862A1 (ko)
IL (1) IL264161A (ko)
MA (1) MA45690A (ko)
MX (1) MX2019000514A (ko)
SG (1) SG11201900200XA (ko)
WO (1) WO2018013939A1 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220025174A (ko) 2013-08-01 2022-03-03 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
CN109071646A (zh) 2016-03-11 2018-12-21 供石公司 TGFβ1-结合免疫球蛋白及其用途
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3820896A1 (en) * 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
MA54845A (fr) 2019-01-30 2021-09-29 Scholar Rock Inc Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations
BR112022007632A2 (pt) * 2019-10-25 2022-07-12 Daiichi Sankyo Co Ltd Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
AU2022355388A1 (en) * 2021-09-30 2024-03-14 Betta Pharmaceuticals Co., Ltd Bispecific antibody and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2284194A1 (en) * 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
EP1910550A4 (en) * 2005-07-21 2009-11-04 Abbott Lab MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2573175B1 (en) * 2010-05-18 2020-07-08 Medical and Biological Laboratories Co., Ltd. ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
RS56624B1 (sr) * 2012-10-02 2018-03-30 Bristol Myers Squibb Co Kombinacija anti-kir antitela i anti-pd-1 antitela u lečenju kancera
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
KR20220025174A (ko) 2013-08-01 2022-03-03 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US11597778B2 (en) * 2015-04-07 2023-03-07 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to ADAMTS13 and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體

Also Published As

Publication number Publication date
MA45690A (fr) 2019-05-22
IL264161A (en) 2019-02-28
JP2022153406A (ja) 2022-10-12
AU2017294772B2 (en) 2024-05-02
JP7128801B2 (ja) 2022-08-31
EP3484499A4 (en) 2020-05-13
US20210277100A1 (en) 2021-09-09
AU2017294772A1 (en) 2019-01-31
CN110049773A (zh) 2019-07-23
JP2019524094A (ja) 2019-09-05
CA3030862A1 (en) 2018-01-18
KR20190034560A (ko) 2019-04-02
BR112019000621A2 (pt) 2019-04-24
WO2018013939A1 (en) 2018-01-18
MX2019000514A (es) 2019-07-12
US20190292254A1 (en) 2019-09-26
KR102577551B1 (ko) 2023-09-11
EP3484499A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201901210UA (en) Ferroelectric memory cells
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806650VA (en) Systems and methods for providing a personal distributed ledger
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201908131RA (en) Benzazepine compounds, conjugates, and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201900269XA (en) Channel sensing for independent links
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201907820SA (en) Inhibitors of (alpha-v)(beta-6) integrin
SG11201909949XA (en) Targeted immunotolerance
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808125RA (en) Methods for solid tumor treatment
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201901168UA (en) Apparatuses and methods including ferroelectric memory and for operating ferroelectric memory
SG11201806496SA (en) Antigen binding proteins that bind pd-l1